Functional Assessments in Vision Impairment
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Retinitis Pigmentosa (RP), Diabetic Retinopathy (DR), Age Related Macular Degeneration (AMD), Glaucoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Australia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Novel Approach for Capturing Real-world Functional Assessment Outcomes in Participants With a Vision Impairment
Overview
The aim of the research project is to validate the use of a novel functional assessment tool designed to document how participants with a vision impairment complete activities of daily living in a real world environment.
Detailed description
There is currently no multisensory tool to assess functional vision in people with a vision impairment. This study is designed to capture and assess the reliability and validity of a novel tool developed by multi-disciplinary experts in ophthalmology, optometry, orthoptics, orientation and mobility (O\&M) specialists, and people with lived experience of low vision. The tool is designed to be used in both clinical and in interventional clinical trial setting, to provide functional vision assessment measures within real-world outcomes. The development of this tool is at a critical junction in time where a range, of interventions are being developed for people with low vision including bionic eyes, and gene and cell therapies. The FDA requires trials to show real world functional outcomes in addition to traditional endpoints, hence a tool like the ATOMM may have wide use and implications. This study will recruit participants with varying levels of vision impairment to assess the reliability of the ATOMM.
Primary outcome measures
- Evaluating validity and reliability [Time frame: From enrolment to assessment could range from 2 to 4 weeks.]
Eligibility criteria
Inclusion criteria
- Willing to provide signed informed consent.
- Be available for study visits.
- Willing to comply with study assessments.
- In good general health and ambulant.
- Aged over 18 years of age.
- Have a vision impairment caused by any ocular condition which affects independent mobility.
- Agree to allow the research team into their home and local environments.
- Participate in assessments in public settings
Exclusion criteria
- Significant co-morbidities which prohibit involvement in study visits.
- Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
- Cognitive deficiencies, including dementia or progressive neurological disease.
- Have a psychiatric condition that, in the investigator's opinion, precludes compliance with the protocol including past or present psychoses and bipolar disorder.
- Deafness or significant hearing loss.
- Inability to converse in English.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
Australia · 1 center
- Centre for Eye Research Australia — Melbourne
Identifiers
NCT: NCT06908161 · 24/1642H